In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Retinal implant developer Second Sight's initial public offering nets $34.8mm

Executive Summary

Second Sight Medical Products Inc. (implantable retinal prostheses for blind patients) netted $34.8mm in its initial public offering of 4.2mm shares (including the overallotment) at $9, as planned. Each of the IPO shares comes with a non-transferable right for the holder to obtain one additional share at no cost on the second anniversary of the IPO.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Radiofrequency Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies